FDA Establishes Susceptibility Breakpoints for Tebipenem Pivoxil, First Oral Carbapenem Approved in U.S.

QC microbiology labs at manufacturing and contract testing sites now have defined susceptibility criteria to work against: FDA has published minimum inhibitory concentration (MIC) and disk diffusion breakpoints for tebipenem pivoxil, the first oral carbapenem to reach the U.S. market, indicated for complicated urinary tract infections (cUTI).

The published breakpoints for Enterobacterales set susceptible at ≤0.12 mcg/mL, intermediate at 0.25 mcg/mL, and resistant at ≥0.5 mcg/mL by MIC. Disk diffusion zone diameter interpretations follow the same three-tier structure: susceptible at ≥29 mm, intermediate at 24–28 mm, and resistant at ≤23 mm. Clinical efficacy data supporting these thresholds were derived from cUTI patients infected with Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, and Klebsiella oxytoca.

For disk diffusion testing, the method specification requires paper disks impregnated with 10 mcg tebipenem. Labs that have not yet sourced or qualified these disks will need to initiate procurement and method validation before tebipenem pivoxil products move through release or stability testing workflows. Under 21 CFR Part 211 laboratory controls requirements, any new antimicrobial susceptibility method must be qualified against established performance criteria prior to use in product disposition decisions.

The broader compliance read for QA directors centers on ICH Q10-aligned change control: introducing a new disk diffusion method, even for a single new compound, triggers documentation requirements around equipment qualification, analyst training, and reference strain suitability. Sites supporting multiple sponsors or contract manufacturers should assess whether existing Enterobacterales reference panels cover the four species for which clinical efficacy was demonstrated, and update standard operating procedures accordingly.

Regulatory affairs leads tracking antimicrobial product submissions should note that these breakpoints now constitute the FDA-recognized interpretive criteria for tebipenem pivoxil, meaning any NDA or ANDA referencing susceptibility data for this compound will be evaluated against this framework going forward.

The disk specification and breakpoint table are now posted to FDA's development resources page, giving labs a defined starting point for SOP drafting and method validation timelines ahead of anticipated commercial distribution.

Source: U.S. Food and Drug Administration, Drugs Development Resources via FDA.gov RSS Feed, 17 June 2026.